Pagnanelli Gianluca - IDI - Istituto Dermopatico dell'Immacolata

Dr.

Gianluca

Pagnanelli

Ruolo in Idi

Responsabile unità operativa semplice

Ambulatorio

Long Covid Dermatologico

Long Covid Dermatologico

Specializzazione

Dermatologia e venereologia

Localizzazione

Attività di Servizio Sanitario Nazionale

Si

Attività di Ambulatorio Privato

Si

Lingue parlate

Italiano, Inglese

Contatti

Expertise clinica

Psoriasi, melanoma, epiluminescenza, chirurgia dermatologica, laserterapia, crioterapia

Biografia

Dott. Gianluca Pagnanelli

1997 Laurea in Medicina e Chirurgia, Università di “Tor Vergata”, Roma
2001 Specializzazione in Dermatologia e Venereologia Università di “Tor Vergata”, Roma
2005 Consulente Dermatologo, Poliambulatorio Guardia di Finanza, Roma
2009 Dirigente medico Dermatologo IDI-IRCCS Roma
2017 Principal Investigator Novartis Study CAIN 457A3403 (SERENA)
2020 Principal Investigator Novartis Study CAIN 457AIT09 (SUPREME2)
2021 Principal Investigator Almirall Study AT10112 (SAIL)

Attività di ricerca: Psoriasi, Tumori cutanei, Epiluminescenza, Melanoma, Teledermatologia.

Attività didattica e scientifica

Pubblicazioni

2024 Apr 7 - International journal of dermatology - Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real-world study.

2023 - Clinical, cosmetic and investigational dermatology - Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study.

2023 - Drugs in context - Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience.

2022 - Frontiers in medicine - Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosis.

2022 Jun - Dermatologic therapy - Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.

2022 Jun - Dermatologic therapy - Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.

2022 Jan - European journal of pediatrics - Correction to: Differences in individual and environmental factors between cutaneous melanoma and atypical Spitz tumour in children and adolescents.

2021 Sep - Expert opinion on biological therapy - Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy.

2022 Jan - European journal of pediatrics - Differences in individual and environmental factors between cutaneous melanoma and atypical Spitz tumour in children and adolescents.

2021 Oct 21 - Acta dermato-venereologica - Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.

2021 Mar 31 - Acta dermato-venereologica - Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.

2020 Oct 1 - European journal of dermatology : EJD - Mild therapeutic response of alopecia areata during treatment of psoriasis with secukinumab.

2020 - PloS one - Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses.

2020 Apr 22 - International journal of molecular sciences - Multiple Sclerosis Treatment and Melanoma Development.

2019 Nov 15 - International journal of molecular sciences - Melanoma and Vitiligo: In Good Company.

2020 Jan - The journal of pathology. Clinical research - Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis development.

2018 Oct 30 - Cell death & disease - IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment.

2018 Mar - Journal of the American Academy of Dermatology - Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.

2018 Aug - Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia - Desmoplastic melanoma: a diagnostic challenge.

2017 Jun 1 - European journal of dermatology : EJD - Tattoo and warts: efficacy of topical immunotherapy.

2017 Oct - International journal of dermatology - Scleredema of Buschke with prominent periorbital edema.

2013 Jun - JAMA dermatology - Dermoscopic evaluation of nodular melanoma.

2008 Sep - Archives of dermatology - Dermoscopic evaluation of amelanotic and hypomelanotic melanoma.

2007 Jul-Aug - Anticancer research - Clinical and dermoscopic criteria related to melanoma sentinel lymph node positivity.

2004 - Journal of telemedicine and telecare - Diagnosis and categorization of acral melanocytic lesions using teledermoscopy.

Numeri utili:

CUP

Assicurazione e Attività Privata

Numeri utili: CUP06 6646 4094,

Assicurazione e Attività Privata 06 6646 4499

© Fondazione Luigi Maria Monti – Sede Legale: Via Monti di Creta 104, 00167 Roma – PEC: fondazioneluigimariamonti@legalmail.it – CF 97831400581 – PI 13326621003
Informative e Privacy – Gestisci Cookie – Social media policy – Limitazione di responsabilità

Sito aggiornato al 03/05/2024 ore 11:00

SHORT LINK

La ricerca in IDI è finanziata da:

I NOSTRI SOCIAL

© Fondazione Luigi Maria Monti – Sede Legale: Via Monti di Creta 104, 00167 Roma – PEC: fondazioneluigimariamonti@legalmail.it – CF 97831400581 – PI 13326621003
Informative e Privacy – Gestisci Cookie – Social media policy – Limitazione di responsabilità

Sito aggiornato al 03/05/2024 ore 11:00

Powered by

Powered by